A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours) | MicrobiomeTrials← Back to trialsNCT07306559
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2026-02-27Est. Completion: 2029-09-07
Enrollment target: 187 participants Locations- Valkyrie Clinical Trials, Los Angeles, California, United States
- Indiana University, Indianapolis, Indiana, United States
- The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- Cliniques Universitaires Saint-Luc, Brussels, Belgium
- UZ Leuven, Leuven, Belgium
- INS Paoli-Calmettes, Marseille, France
- Institut Gustave Roussy, Villejuif, France
- Klinikum der Universität München AÖR, München, Germany
- Universitätsklinikum Würzburg AÖR, Würzburg, Germany
- National Cancer Center Hospital East, Chiba, Kashiwa, Japan
- Japanese Foundation for Cancer Research, Tokyo, Koto-ku, Japan
- Hospital Universitari Vall d'Hebron, Barcelona, Spain
- Clínica Universidad de Navarra - Madrid, Madrid, Spain
Other microbiome trials you might be interested in
Cutaneous MelanomaRelapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID)Metastatic Cutaneous Melanoma (Stage IV)
The goal of this clinical trial is to learn about the effectiveness and safety of the bispecific antibody acasunlimab (a…
Nashville, United StatesEst. completion Jul 15, 2027
ColitisHepatitisMelanoma (Skin Cancer)
Extracorporeal photopheresis (ECP) is an immunomodulatory therapy in which the photoactivating agent methoxsalen (also k…
Boehringer Ingelheim
Multiple LocationsEst. completion Dec 2028